Her Highness Sheikha Moza bint Nasser Attends Sidra Medicine’s Disease Modeling and Therapeutics Conference

Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation for Education, Science and Community Development (QF) today attended Sidra Medicine’s first Disease Modeling and Therapeutics (DMT) conference.  

The opening plenary included several keynote addresses, and underscored Qatar’s commitment to advancing research and therapeutic innovation for diseases of global significance. His Excellency Mansoor bin Ebrahim bin Saad Al Mahmoud, the Minister of Public Health and other dignitaries were also in attendance at the conference.

Dr. Iyabo Tinubu-Karch, CEO of Sidra Medicine, said: “DMT 2025 is a platform where world-class innovation meets collaboration, driving forward our mission to position Sidra Medicine and, in turn, Qatar as leaders in transformative healthcare. It also highlights our commitment to knowledge-sharing and collaborating on pioneering research techniques, technologies and medical discoveries that improve lives locally and globally.”

Highlights from the opening featured keynote addresses by pioneering scientists whose research is shaping the future of diabetes care. The keynote speakers were also part of a panel discussion Translating Stem Cell Research into Clinical Applications for Diabetes. The first Disease Modeling and Therapeutics conference marks a milestone in Qatar’s journey to bring the country to the forefront of conversations that are shaping the future of regenerative medicine.

Prof. Khalid Fakhro, Chief Research Officer at Sidra Medicine noted: “Sidra Medicine is committed to advancing the integration of research and healthcare, particularly around conditions that have a profound impact on our community. By convening global experts here in Doha, we ensure that the latest breakthroughs in disease modeling and cell-based therapies are not only shared but contextualized for our local population needs. We are committed to accelerating research translation into clinical practice, and to strengthen Qatar’s role in global medical innovation.”

Through collaborative sessions and invaluable discussions, DMT 2025 aims to emphasize the importance of disease modeling technologies and their application to personalized therapies. Co-chaired by Principal Investigators Dr. Essam Abdelalim and Dr. Luis Saraiva, from Sidra Medicine, the conference will conclude on 30 September 2025.